FDA Issues Safety Alert for Philips Lumify Ultrasound Due to Software Issue
The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding Philips' Lumify Diagnostic Ultrasound System due to a software issue that is preventing the device from functioning properly during scans. The problem reportedly led to delays in diagnosis, which may have contributed to patient harm or death. Philips’ Lumify system is widely used for diagnostic imaging and relies on cloud-based technology. The FDA has urged healthcare providers using this product to monitor its performance closely and report any adverse events related to the issue. Philips has been working with the agency to address the problem, though no specific resolution timeline was provided. The alert highlights concerns about medical device reliability in a digital health landscape increasingly dependent on software integration.
Tickers: $PHG